In this issue:
Sustained efficacy for pembrolizumab plus axitinib in advanced RCC
Serial metastasis-directed radiotherapy alone for oligometastatic RCC
Neoadjuvant TAR-200/cetrelimab combo promising for resectable bladder cancer
Real-world effectiveness of 177Lu-PSMA for previously treated mCRPC
Long-term survival benefit to ADT + radiotherapy for recurrent prostate cancer
HRQoL with cystectomy vs bladderpreserving therapy for MIBC
PERSEUS1: Pembrolizumab for dMMR mCRC
Predictive biomarkers of response to adjuvant nivolumab in MIBC
Enfortumab vedotin + pembrolizumab durably bests chemo for urothelial carcinoma
Does delayed prostatectomy affect pathological progression in prostate cancer?
Please login below to download this issue (PDF)